Skip to main navigation Skip to search Skip to main content

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

  • Alexa B. Kimball
  • , Gregor B.E. Jemec
  • , Christopher J. Sayed
  • , Joslyn S. Kirby
  • , Errol Prens
  • , John R. Ingram
  • , Amit Garg
  • , Alice B. Gottlieb
  • , Jacek C. Szepietowski
  • , Falk G. Bechara
  • , Evangelos J. Giamarellos-Bourboulis
  • , Hideki Fujita
  • , Robert Rolleri
  • , Paulatsya Joshi
  • , Pratiksha Dokhe
  • , Edward Muller
  • , Luke Peterson
  • , Cynthia Madden
  • , Muhammad Bari
  • , Christos C. Zouboulis

Research output: Contribution to journal › Article › peer-review

145   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology